

Best practices and recent advances in the management of worsening heart failure

Chair

Burkert Pieske, MD, Charité University Medicine and German Heart Center, Berlin, Germany

Faculty

Javed Butler, MD, Baylor Scott and White Research Institute and University of Mississippi Medical Center, Jackson, US

Carolyn Lam, MD, Duke-NUS Medical School and National Heart Centre, Singapore

Shelley Zieroth, MD, University of Manitoba and Cardiac sciences, Manitoba, Winnipeg, Canada

Release date: 13 May 2022

Expiration date: 12 May 2023

Estimated time to completion for accredited round-table: 1.0 hour

Available CME credits: UEMS-EACCME® accreditation pending

Activity description

This educational activity consists of one expert discussion on the management of worsening heart failure (HF), which will be submitted for accreditation. It also includes two interactive patient cases with narration, and an interactive infographic on worsening HF.

During the expert discussion, leading experts will provide you with

- An overview of worsening HF and its burden on patient's quality of life
- Updates on clinical guidelines on worsening HF and current recommendations for current background therapy in HF
- A review of key outcomes of clinical trials in HF relevant to worsening HF
- Insights on follow-up of worsening HF, including relevant guideline recommendations for clinical practice

The two interactive patient cases, each of 10 minutes' duration, will cover the impact of worsening HF on patients' lives, and its appropriate management, specifically

- Guidance on the clinical management of an acute event of worsening HF
- Insights into the clinical management of a patient in the follow-up period after a worsening HF event

The interactive infographic will provide an overview of the importance of worsening events in HF with reduced ejection fraction, including key aspects of its clinical management.

Target audience

Cardiologists, cardiology nurse practitioners, cardiology physician assistants, hospitalists/internal medicine specialists, primary care physicians, and other healthcare professionals involved in the management of HF.

Educational objectives

After completing this activity, the participant should be better able to

- **Recognize** the importance of worsening HF and the implications for the patient's quality of life
- **Discuss** the latest updates on international clinical practice guidelines and evaluate recent clinical trial data for worsening HF
- **Implement** individualized treatment plans for the optimal clinical management and follow-up of patients with worsening HF

Physician Continuing Medical Education

An application for accreditation (1.0 ECMEC®) has been submitted to UEMS-EACCME® for this educational activity.

Method of participation

There are no fees for participating in this activity.

1. Read the educational objectives, accreditation information, and faculty disclosures
2. Complete the webcast and two interactive patient case activities
3. Take the post-activity test and complete the evaluation

Disclosure of conflicts of interest

Faculty	Relationship identified with:
Carolyn Lam	Receipt of grants/research supports: Bayer, Roche Diagnostics. Receipt of honoraria or consultation fees: Abbott, Actelion, Allysta Pharmaceuticals, Amgen, AnaCardio, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous, Impulse Dynamics, Ionis, Janssen Research & Development, Medscape/WebMD Global, Merck, Novartis, Novo Nordisk, Prosciento, Radcliffe Group, Roche Diagnostics, Sanofi, Siemens Healthcare, Us2.AI.
Javed Butler	Receipt of honoraria or consultation fees: Abbott, Adrenomed, Amgen, Applied Therapeutics, Array BioPharma, AstraZeneca, Bayer, Boehringer

	<p>Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceuticals, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold Pharmaceuticals, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa / Vifor Pharma, Roche, Sequana Medical, Vifor Pharma.</p> <p>Participation in a company-sponsored speaker's bureau: AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Novartis</p>
Burkert Pieske	None
Shelley Zieroth	<p>Receipt of grants/research supports: Novartis, Servier.</p> <p>Receipt of honoraria or consultation fees: Abbott, Akcea Therapeutics, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Servier, Vifor Pharma.</p> <p>Participation in a company sponsored speaker's bureau: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, HLS Therapeutics, Janssen, Novartis, Servier, Vifor Pharma.</p> <p>Other support (please specify): Clinical trials: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eidos, Merck, Novartis.</p> <p>Steering Committee: PARAGLIDE-HF. National Lead: EMPACT-MI, EMPULSE, FINE-ARTS, DETERMINE, VICTOR.</p>

Planners and managers

The Ology Medical Education planners and managers have nothing to disclose.

Provider information

Provided by Ology Medical Education.



Financial support

This activity is supported by an independent educational grant from Bayer AG, Germany.

Disclosure of unlabeled use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labelled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The course materials are for educational purposes only and should not be reproduced or distributed in any way. If you wish to reproduce, store in a retrieval system, transmit in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, any part of the material presented, you will need to obtain all the necessary permissions by writing to the publisher, the original author, or any other current copyright owner.

Contact information for questions about the activity

info@ologyeducation.org, www.ologyeducation.org

System requirements

Ology Education requires a modern web browser (Google Chrome, Mozilla Firefox, Apple Safari, Microsoft Edge). Certain educational activities may require a PDF reader such as Adobe Acrobat Reader to view.

Policy on privacy and confidentiality

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

Media

Internet